STAT

Kale crackers and hibiscus tea: My five days on a ‘fasting diet’

I tried the five-day ProLon diet, an ultra-low-calorie regimen meant to trick your body into thinking you're fasting. It wasn't as bad as I'd feared.

LOS ANGELES — The box is lovely, sleek and white. But it’s so small.

I’ve decided to try the ProLon diet — five days of “mimicking fasting” that is supposed to help me lose weight, trim belly fat, drop my cholesterol and glucose levels into healthier zones, and even slow aging. I’ve been researching the science behind fasting — check out my full story on that topic here — so I’m excited to try it myself.

But the box is so small. Not much larger than a shoebox, it contains all the food and drink, other than water, that I’ll get for five days. I sift through the futuristic-looking — and tiny — packets of olives and freeze-dried soups, kale chips, and nut bars. I love food so much. I’m a little bit worried.

The diet consists of an ultra-low-calorie blend of proteins, carbohydrates, fats, and nutrients that’s meant to trick the body into thinking it is fasting, but with less discomfort or risk than a true water-only fast. That’s according to its inventor, biochemist Valter Longo, the director of the Longevity Institute at the University of Southern California.

He’s launched a company, L-Nutra, to market the diet; it’s sold for $300 per

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks